


Healthcare News Roundup: Biopharmaceutical
HSMN NewsFeed - 5 Feb 2007
Amarin Announces Completion of Two Phase III Trials With Miraxion in Huntington's Disease
Amarin Announces Completion of Two Phase III Trials With Miraxion in Huntington's Disease
HSMN NewsFeed - 5 Feb 2007
Wyeth Pharmaceuticals and MediVas Announce Research Partnership to Develop Advanced Hemophilia Therapies
Wyeth Pharmaceuticals and MediVas Announce Research Partnership to Develop Advanced Hemophilia Therapies
HSMN NewsFeed - 5 Feb 2007
AstraZeneca Licenses Regeneron's VelocImmune(R) Technology for Discovering Human Monoclonal Antibodies
AstraZeneca Licenses Regeneron's VelocImmune(R) Technology for Discovering Human Monoclonal Antibodies
HSMN NewsFeed - 5 Feb 2007
Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to Develop Hemophilia Therapies
Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to Develop Hemophilia Therapies
HSMN NewsFeed - 2 Feb 2007
Survey Indicates People with Chronic Moderate to Severe Plaque Psoriasis May Be Under-Treated
Survey Indicates People with Chronic Moderate to Severe Plaque Psoriasis May Be Under-Treated
HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
HSMN NewsFeed - 2 Feb 2007
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
HSMN NewsFeed - 2 Feb 2007
FDA Approves New Dosing Recommendations for RAPAMUNE in High Immunologic Risk Renal Transplant Patients
FDA Approves New Dosing Recommendations for RAPAMUNE in High Immunologic Risk Renal Transplant Patients
HSMN NewsFeed - 2 Feb 2007
Schering-Plough Cites Today's Anacor Agreement as Latest in Series of Deals
Schering-Plough Cites Today's Anacor Agreement as Latest in Series of Deals
HSMN NewsFeed - 2 Feb 2007
GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
HSMN NewsFeed - 2 Feb 2007
DRAXIS Radiopharmaceuticals Division Applies to FDA to Market Cardiac Imaging Product
DRAXIS Radiopharmaceuticals Division Applies to FDA to Market Cardiac Imaging Product
HSMN NewsFeed - 1 Feb 2007
CSL Behring and Bayer Extend Agreement for Supply of Helixate(R) Recombinant Coagulation Factor
CSL Behring and Bayer Extend Agreement for Supply of Helixate(R) Recombinant Coagulation Factor
HSMN NewsFeed - 1 Feb 2007
Anavex Life Sciences Corp. Outlines Its Central Nervous System (CNS) Portfolio of Novel Therapeutics
Anavex Life Sciences Corp. Outlines Its Central Nervous System (CNS) Portfolio of Novel Therapeutics
HSMN NewsFeed - 1 Feb 2007
Hospira Completes Acquisition of Mayne Pharma, Announces New Commercial Leadership Structure
Hospira Completes Acquisition of Mayne Pharma, Announces New Commercial Leadership Structure
HSMN NewsFeed - 1 Feb 2007
VioQuest Pharmaceuticals, Inc. Announces Appointment of Chief Scientific Officer
VioQuest Pharmaceuticals, Inc. Announces Appointment of Chief Scientific Officer
HSMN NewsFeed - 1 Feb 2007
Grifols Announces FDA Approval of Alphanate(R) to Treat von Willebrand Disease
Grifols Announces FDA Approval of Alphanate(R) to Treat von Willebrand Disease
HSMN NewsFeed - 1 Feb 2007
Ranbaxy Receives Final FDA Approval to Manufacture and Market Valacyclovir HCl Tablets
Ranbaxy Receives Final FDA Approval to Manufacture and Market Valacyclovir HCl Tablets
HSMN NewsFeed - 1 Feb 2007
Ivrea Pharmaceuticals Appoints Daniel S. Lynch as President and Chief Executive Officer
Ivrea Pharmaceuticals Appoints Daniel S. Lynch as President and Chief Executive Officer
HSMN NewsFeed - 1 Feb 2007
Fresenius Medical Care and Amgen Enter New Commercial Collaboration in Europe
Fresenius Medical Care and Amgen Enter New Commercial Collaboration in Europe
HSMN NewsFeed - 1 Feb 2007
Fresenius Medical Care and Amgen Establish a Joint Research Program in Europe
Fresenius Medical Care and Amgen Establish a Joint Research Program in Europe
HSMN NewsFeed - 1 Feb 2007
Artes Medical Announces Landmark Five Year Study Results for ArteFill, a Non-Resorbable Dermal Filler
Artes Medical Announces Landmark Five Year Study Results for ArteFill, a Non-Resorbable Dermal Filler
HSMN NewsFeed - 1 Feb 2007
AstraZeneca Acquires Arrow Therapeutics To Broaden Anti-Infective Capabilities
AstraZeneca Acquires Arrow Therapeutics To Broaden Anti-Infective Capabilities
HSMN NewsFeed - 31 Jan 2007
Court Rules In Pfizer's Favor In Norvasc Patent Case, Finds Synthon Obtained Patent By Inequitable Conduct
Court Rules In Pfizer's Favor In Norvasc Patent Case, Finds Synthon Obtained Patent By Inequitable Conduct
HSMN NewsFeed - 31 Jan 2007
Alfacell Appoints David Sidransky M.D. as Vice Chairman and Lead Independent Director
Alfacell Appoints David Sidransky M.D. as Vice Chairman and Lead Independent Director
HSMN NewsFeed - 31 Jan 2007
Ranbaxy Gains FDA Approval to Market Amoxicillin and Clavulanate Potassium for Oral Suspension USP
Ranbaxy Gains FDA Approval to Market Amoxicillin and Clavulanate Potassium for Oral Suspension USP
HSMN NewsFeed - 31 Jan 2007
FDA Advisory Committee to Review DOR BioPharma's orBec(R) for the Treatment of GI GVHD
FDA Advisory Committee to Review DOR BioPharma's orBec(R) for the Treatment of GI GVHD
HSMN NewsFeed - 31 Jan 2007
Theratechnologies Launches Confirmatory Phase 3 Trial Testing TH9507 in HIV-Associated Lipodystrophy
Theratechnologies Launches Confirmatory Phase 3 Trial Testing TH9507 in HIV-Associated Lipodystrophy
HSMN NewsFeed - 31 Jan 2007
NexMed Announces Patient Dosing in Phase 3 Program for Anti-Fungal Product
NexMed Announces Patient Dosing in Phase 3 Program for Anti-Fungal Product
HSMN NewsFeed - 31 Jan 2007
Polydex Pharmaceuticals Reports Phase III Trial of Ushercell for HIV Prevention Halted
Polydex Pharmaceuticals Reports Phase III Trial of Ushercell for HIV Prevention Halted
HSMN NewsFeed - 31 Jan 2007
Mylan Announces Final FDA Approval for Its 12 mcg/hr Fentanyl Transdermal System
Mylan Announces Final FDA Approval for Its 12 mcg/hr Fentanyl Transdermal System
HSMN NewsFeed - 31 Jan 2007
Mylan Announces Tentative Approval for Valacyclovir Hydrochloride Tablets
Mylan Announces Tentative Approval for Valacyclovir Hydrochloride Tablets
HSMN NewsFeed - 30 Jan 2007
YM BioSciences announces termination of the tesmilifene Phase III pivotal trial in advanced breast cancer
YM BioSciences announces termination of the tesmilifene Phase III pivotal trial in advanced breast cancer
HSMN NewsFeed - 30 Jan 2007
AVANIR Receives FDA Approvable Letter for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
AVANIR Receives FDA Approvable Letter for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
HSMN NewsFeed - 30 Jan 2007
TetraLogic Pharmaceuticals Appoints Dr. Andrew Pecora to Its Board of Directors
TetraLogic Pharmaceuticals Appoints Dr. Andrew Pecora to Its Board of Directors
HSMN NewsFeed - 30 Jan 2007
Encore Therapeutics Inc. Reports Efficacy Data on a Long-Acting Local Anesthetic Drug
Encore Therapeutics Inc. Reports Efficacy Data on a Long-Acting Local Anesthetic Drug
HSMN NewsFeed - 30 Jan 2007
Mylan Announces Final FDA Approval for Albuterol Sulfate Extended-Release Tablets
Mylan Announces Final FDA Approval for Albuterol Sulfate Extended-Release Tablets
HSMN NewsFeed - 30 Jan 2007
Javelin Pharmaceuticals Announces Results of FDA Meeting for Nasal Ketamine
Javelin Pharmaceuticals Announces Results of FDA Meeting for Nasal Ketamine
HSMN NewsFeed - 30 Jan 2007
PsychoGenics Announces the Launch of Psylin Neurosciences, Inc. in Partnership with Amylin Pharmaceuticals
PsychoGenics Announces the Launch of Psylin Neurosciences, Inc. in Partnership with Amylin Pharmaceuticals
HSMN NewsFeed - 30 Jan 2007
Merck Serono Launches easypod(R), First Electronic Growth Hormone Injection Device
Merck Serono Launches easypod(R), First Electronic Growth Hormone Injection Device
HSMN NewsFeed - 29 Jan 2007
Pharmion Corporation Announces FDA Approval of Vidaza NDA Supplement for IV Administration
Pharmion Corporation Announces FDA Approval of Vidaza NDA Supplement for IV Administration
HSMN NewsFeed - 29 Jan 2007
Somaxon Pharmaceuticals Names Robert Jones Vice President, Human Resources
Somaxon Pharmaceuticals Names Robert Jones Vice President, Human Resources
HSMN NewsFeed - 29 Jan 2007
Obagi Medical Products, Inc. Launches CLENZIderm M.D. Penetrating Acne Therapeutic System
Obagi Medical Products, Inc. Launches CLENZIderm M.D. Penetrating Acne Therapeutic System
HSMN NewsFeed - 26 Jan 2007
Schering-Plough Corporation Mourns Death of Bruce R. Reid, Leader in Pharmaceutical Business
Schering-Plough Corporation Mourns Death of Bruce R. Reid, Leader in Pharmaceutical Business
HSMN NewsFeed - 26 Jan 2007
Astellas and Pfizer Reached Settlement on Declaratory Judgment Action Relating to Lipitor Agreement
Astellas and Pfizer Reached Settlement on Declaratory Judgment Action Relating to Lipitor Agreement
HSMN NewsFeed - 26 Jan 2007
Oscient Pharmaceuticals Completes Enrollment in Phase IV Trial of FACTIVE Tablets
Oscient Pharmaceuticals Completes Enrollment in Phase IV Trial of FACTIVE Tablets
HSMN NewsFeed - 26 Jan 2007
GenVec Announces First Patient Treated with TNFerade(TM) for Head and Neck Cancer at University of Chicago
GenVec Announces First Patient Treated with TNFerade(TM) for Head and Neck Cancer at University of Chicago
HSMN NewsFeed - 25 Jan 2007
James Shaffer Joins New River Pharmaceuticals as Vice President, Sales and Marketing
James Shaffer Joins New River Pharmaceuticals as Vice President, Sales and Marketing
HSMN NewsFeed - 25 Jan 2007
Bayer Discontinues Trasylol(R) Clinical Trial Program in Non-CABG Indications
Bayer Discontinues Trasylol(R) Clinical Trial Program in Non-CABG Indications
HSMN NewsFeed - 25 Jan 2007
Valeant Pharmaceuticals Developing Intranasal Diazepam for the At-Home Treatment of Emergency Seizures
Valeant Pharmaceuticals Developing Intranasal Diazepam for the At-Home Treatment of Emergency Seizures
HSMN NewsFeed - 25 Jan 2007
Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma
Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma
HSMN NewsFeed - 25 Jan 2007
WuXi PharmaTech Fills Two Key Leadership Positions with Internal Candidates
WuXi PharmaTech Fills Two Key Leadership Positions with Internal Candidates
HSMN NewsFeed - 25 Jan 2007
Spectrum Pharmaceuticals Initiates Phase 2b Trial for Ozarelix in Patients with Benign Prostate Hypertrophy
Spectrum Pharmaceuticals Initiates Phase 2b Trial for Ozarelix in Patients with Benign Prostate Hypertrophy
HSMN NewsFeed - 25 Jan 2007
BioCryst Initiates Phase II Influenza Clinical Trial to Evaluate Peramivir
BioCryst Initiates Phase II Influenza Clinical Trial to Evaluate Peramivir
HSMN NewsFeed - 24 Jan 2007
Cephalon Comments on Study of its Leukemia Treatment Led by National Cancer Institute Cooperative Group
Cephalon Comments on Study of its Leukemia Treatment Led by National Cancer Institute Cooperative Group
HSMN NewsFeed - 24 Jan 2007
Zylera Pharmaceuticals Announces Availability of RELAMINE for the Treatment of Osteoarthritis
Zylera Pharmaceuticals Announces Availability of RELAMINE for the Treatment of Osteoarthritis
HSMN NewsFeed - 24 Jan 2007
Teva Files Patent Infringement Complaints Regarding Sertraline Hydrochloride
Teva Files Patent Infringement Complaints Regarding Sertraline Hydrochloride
HSMN NewsFeed - 24 Jan 2007
Introgen Reports that INGN 241 in Combination with Avastin(R) Results in Complete Tumor Regression
Introgen Reports that INGN 241 in Combination with Avastin(R) Results in Complete Tumor Regression
HSMN NewsFeed - 24 Jan 2007
Point Therapeutics Announces Resignation of William Whelan from Board of Directors
Point Therapeutics Announces Resignation of William Whelan from Board of Directors
HSMN NewsFeed - 24 Jan 2007
Vical Highlights Transition to Phase 3 Trial With Allovectin-7(R) for Metastatic Melanoma
Vical Highlights Transition to Phase 3 Trial With Allovectin-7(R) for Metastatic Melanoma
HSMN NewsFeed - 23 Jan 2007
Amicus Therapeutics Receives Grant From Michael J. Fox Foundation for Parkinson's Research
Amicus Therapeutics Receives Grant From Michael J. Fox Foundation for Parkinson's Research
HSMN NewsFeed - 23 Jan 2007
Synta Pharmaceuticals Corp. Announces Additions to Senior Management Team
Synta Pharmaceuticals Corp. Announces Additions to Senior Management Team
HSMN NewsFeed - 23 Jan 2007
Barr's Subsidiary PLIVA Receives Approval for Generic ZITHROMAX(R) IV, 500 mg Vial
Barr's Subsidiary PLIVA Receives Approval for Generic ZITHROMAX(R) IV, 500 mg Vial
HSMN NewsFeed - 23 Jan 2007
Safety Monitoring Board Recommends Continuation of EntreMed's MKC-1 Phase 2 Breast Cancer Study
Safety Monitoring Board Recommends Continuation of EntreMed's MKC-1 Phase 2 Breast Cancer Study
HSMN NewsFeed - 23 Jan 2007
Akorn, Inc. Announces Positive Phase III Pivotal Trial Results for Akten(R)
Akorn, Inc. Announces Positive Phase III Pivotal Trial Results for Akten(R)
HSMN NewsFeed - 22 Jan 2007
Neurocrine Announces Plans to Resubmit NDA for Indiplon Capsules in Q2 2007
Neurocrine Announces Plans to Resubmit NDA for Indiplon Capsules in Q2 2007
HSMN NewsFeed - 22 Jan 2007
Cytokinetics Announces Changes to its Executive Management Team and Board of Directors
Cytokinetics Announces Changes to its Executive Management Team and Board of Directors
HSMN NewsFeed - 22 Jan 2007
iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema
iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema
HSMN NewsFeed - 22 Jan 2007
Plaintiff Drops VIOXX(R) Suit against Merck Five Weeks Before First Trial in Philadelphia State Court
Plaintiff Drops VIOXX(R) Suit against Merck Five Weeks Before First Trial in Philadelphia State Court
HSMN NewsFeed - 22 Jan 2007
BioMS Medical cleared by FDA to initiate pivotal phase III multiple sclerosis trial
BioMS Medical cleared by FDA to initiate pivotal phase III multiple sclerosis trial
HSMN NewsFeed - 22 Jan 2007
Isis Announces Appointment of Jeffrey M. Jonas, M.D. as Executive Vice President
Isis Announces Appointment of Jeffrey M. Jonas, M.D. as Executive Vice President
HSMN NewsFeed - 19 Jan 2007
Takeda Global Research & Development Center, Inc. Names Dr. Mehmood Khan President
Takeda Global Research & Development Center, Inc. Names Dr. Mehmood Khan President
HSMN NewsFeed - 19 Jan 2007
Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor for Capsaicin-induced Pain
Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor for Capsaicin-induced Pain
HSMN NewsFeed - 19 Jan 2007
Barr Launches Generic METAGLIP(TM) Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg
Barr Launches Generic METAGLIP(TM) Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg
HSMN NewsFeed - 19 Jan 2007
Bayer Schering Pharma to Develop New Imaging Compounds for Detection of Neurodegenerative Diseases
Bayer Schering Pharma to Develop New Imaging Compounds for Detection of Neurodegenerative Diseases
HSMN NewsFeed - 18 Jan 2007
Cipralex Approved in Europe for the Treatment of Obsessive Compulsive Disorder
Cipralex Approved in Europe for the Treatment of Obsessive Compulsive Disorder
HSMN NewsFeed - 18 Jan 2007
Barr Receives Tentative Approval for Generic KYTRIL(R) Tablets, 1mg (Base)
Barr Receives Tentative Approval for Generic KYTRIL(R) Tablets, 1mg (Base)
HSMN NewsFeed - 18 Jan 2007
Alpharma Names Executive Vice President, Human Resources and Communication
Alpharma Names Executive Vice President, Human Resources and Communication
HSMN NewsFeed - 17 Jan 2007
Endo Pharmaceuticals Receives Subpoena From U.S. Department of Health and Human Services
Endo Pharmaceuticals Receives Subpoena From U.S. Department of Health and Human Services
HSMN NewsFeed - 17 Jan 2007
Archemix and Merck KGaA to Collaborate on Aptamer-Based Cancer Therapeutics
Archemix and Merck KGaA to Collaborate on Aptamer-Based Cancer Therapeutics
HSMN NewsFeed - 17 Jan 2007
GlaxoSmithKline Awarded $63 Million HHS Contract for Pandemic Vaccine Research and Development
GlaxoSmithKline Awarded $63 Million HHS Contract for Pandemic Vaccine Research and Development
HSMN NewsFeed - 17 Jan 2007
Sirion Therapeutics Acquires U.S. License to Develop New Treatment for Viral Eye Infection
Sirion Therapeutics Acquires U.S. License to Develop New Treatment for Viral Eye Infection
HSMN NewsFeed - 17 Jan 2007
John Z. Sullivan-Bolyai, M.D., MPH, Joins Anadys Pharmaceuticals as Vice President, Clinical Affairs
John Z. Sullivan-Bolyai, M.D., MPH, Joins Anadys Pharmaceuticals as Vice President, Clinical Affairs
HSMN NewsFeed - 17 Jan 2007
Bradley Pharmaceuticals Welcomes Alton Delane, Vice President, Business Development
Bradley Pharmaceuticals Welcomes Alton Delane, Vice President, Business Development
HSMN NewsFeed - 16 Jan 2007
Peregrine Pharmaceuticals' Tumor Necrosis Therapy Product for the Treatment of Lung Cancer Launched in China
Peregrine Pharmaceuticals' Tumor Necrosis Therapy Product for the Treatment of Lung Cancer Launched in China
HSMN NewsFeed - 16 Jan 2007
CEL-SCI Receives Green Light From FDA to Proceed With Phase III Cancer Study
CEL-SCI Receives Green Light From FDA to Proceed With Phase III Cancer Study
HSMN NewsFeed - 16 Jan 2007
Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria
Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria
HSMN NewsFeed - 16 Jan 2007
Reliant Pharmaceuticals Names Bradley T. Sheares, Ph.D. Chief Executive Officer
Reliant Pharmaceuticals Names Bradley T. Sheares, Ph.D. Chief Executive Officer
HSMN NewsFeed - 16 Jan 2007
Watson Announces Positive Phase 3 Study Results on Silodosin for Treatment of Benign Prostatic Hyperplasia
Watson Announces Positive Phase 3 Study Results on Silodosin for Treatment of Benign Prostatic Hyperplasia
HSMN NewsFeed - 16 Jan 2007
Nabi Biopharmaceuticals Announces Initiation of Civacir(R) Phase II 'Proof-of- Concept' Clinical Trial
Nabi Biopharmaceuticals Announces Initiation of Civacir(R) Phase II 'Proof-of- Concept' Clinical Trial
HSMN NewsFeed - 16 Jan 2007
Harold F. Oberkfell Succeeds Steven A. Elms as Chairman of Adams Respiratory Therapeutics
Harold F. Oberkfell Succeeds Steven A. Elms as Chairman of Adams Respiratory Therapeutics
HSMN NewsFeed - 16 Jan 2007
Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Accepted for Filing by FDA
Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Accepted for Filing by FDA
HSMN NewsFeed - 16 Jan 2007
Aradigm Receives FDA Orphan Drug Designation for Liposomal Ciprofloxacin for Bronchiectasis
Aradigm Receives FDA Orphan Drug Designation for Liposomal Ciprofloxacin for Bronchiectasis
HSMN NewsFeed - 16 Jan 2007
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
HSMN NewsFeed - 15 Jan 2007
Lux Biosciences Receives Orphan Drug Designation from the FDA for Two Ophthalmic Products
Lux Biosciences Receives Orphan Drug Designation from the FDA for Two Ophthalmic Products
HSMN NewsFeed - 15 Jan 2007
FDA Accepts for Filing a New Drug Application (NDA) for Somatuline(R) Autogel(R)
FDA Accepts for Filing a New Drug Application (NDA) for Somatuline(R) Autogel(R)
HSMN NewsFeed - 12 Jan 2007
Pipex Pharmaceuticals Acquires Minority Interest in Its Effective Pharmaceuticals Subsidiary
Pipex Pharmaceuticals Acquires Minority Interest in Its Effective Pharmaceuticals Subsidiary
HSMN NewsFeed - 12 Jan 2007
Catalyst Pharmaceutical Partners, Inc. Adds Thomas Kosten, M.D. to Its Scientific Advisory Board
Catalyst Pharmaceutical Partners, Inc. Adds Thomas Kosten, M.D. to Its Scientific Advisory Board
HSMN NewsFeed - 12 Jan 2007
Point Therapeutics Provides Preliminary Results from Phase 2 Metastatic Pancreatic Cancer Study
Point Therapeutics Provides Preliminary Results from Phase 2 Metastatic Pancreatic Cancer Study
HSMN NewsFeed - 12 Jan 2007
Astellas Pharma US, Inc. Announces Availability of MYCAMINE(R) 100mg Vial
Astellas Pharma US, Inc. Announces Availability of MYCAMINE(R) 100mg Vial
HSMN NewsFeed - 11 Jan 2007
Ash Access Technology, Inc. Appoints Dr. Al Guillem as Vice President, Scientific and Quality Affairs
Ash Access Technology, Inc. Appoints Dr. Al Guillem as Vice President, Scientific and Quality Affairs
HSMN NewsFeed - 11 Jan 2007
Valeant Pharmaceuticals & Metabasis Therapeutics Close Licensing Deal with Schering-Plough Corporation
Valeant Pharmaceuticals & Metabasis Therapeutics Close Licensing Deal with Schering-Plough Corporation
HSMN NewsFeed - 11 Jan 2007
FDA Clears Humanetics' IND Filing to Commence Clinical Studies on New Radiation Countermeasure
FDA Clears Humanetics' IND Filing to Commence Clinical Studies on New Radiation Countermeasure
HSMN NewsFeed - 11 Jan 2007
GenVec Receives Clearance From FDA for EUS Administration of TNFerade(TM)
GenVec Receives Clearance From FDA for EUS Administration of TNFerade(TM)
HSMN NewsFeed - 11 Jan 2007
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
HSMN NewsFeed - 11 Jan 2007
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
HSMN NewsFeed - 10 Jan 2007
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
HSMN NewsFeed - 10 Jan 2007
Endovasc Strengthens Management Team by Appointing Chief Financial and Chief Compliance Officer
Endovasc Strengthens Management Team by Appointing Chief Financial and Chief Compliance Officer
HSMN NewsFeed - 10 Jan 2007
Panacea Pharmaceuticals Appoints Pamela Harris, MD, Vice President Medical and Clinical Affairs
Panacea Pharmaceuticals Appoints Pamela Harris, MD, Vice President Medical and Clinical Affairs
HSMN NewsFeed - 10 Jan 2007
Novo Nordisk Appoints Nathaniel Clark, M.D., as Senior Medical Advisor - Diabetes
Novo Nordisk Appoints Nathaniel Clark, M.D., as Senior Medical Advisor - Diabetes
HSMN NewsFeed - 10 Jan 2007
Italian Ministry of Health Requests IPLEX(TM) for Treatment of ALS (Lou Gehrig's Disease)
Italian Ministry of Health Requests IPLEX(TM) for Treatment of ALS (Lou Gehrig's Disease)
HSMN NewsFeed - 10 Jan 2007
Bradley Pharmaceuticals Announces Appointment of Dr. Leonard S. Jacob As Non-Executive Chair
Bradley Pharmaceuticals Announces Appointment of Dr. Leonard S. Jacob As Non-Executive Chair
HSMN NewsFeed - 10 Jan 2007
Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
HSMN NewsFeed - 10 Jan 2007
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
HSMN NewsFeed - 10 Jan 2007
Basilea Announces Positive Top-Line Results On Second Pivotal Phase III Ceftobiprole Trial
Basilea Announces Positive Top-Line Results On Second Pivotal Phase III Ceftobiprole Trial
HSMN NewsFeed - 9 Jan 2007
Cephalon Announces Positive Results from Two Phase 3 Clinical Trials of FENTORA(TM) in Breakthrough Pain
Cephalon Announces Positive Results from Two Phase 3 Clinical Trials of FENTORA(TM) in Breakthrough Pain
HSMN NewsFeed - 9 Jan 2007
Takeda Pharmaceuticals North America Names Vice President of Human Resources and Administration
Takeda Pharmaceuticals North America Names Vice President of Human Resources and Administration
HSMN NewsFeed - 9 Jan 2007
AVI BioPharma and Eleos Announce Cross-License Agreement for p53 Therapeutics
AVI BioPharma and Eleos Announce Cross-License Agreement for p53 Therapeutics
HSMN NewsFeed - 9 Jan 2007
Biogen Idec Initiates Phase III Clinical Program of Oral Compound BG-12 for Multiple Sclerosis
Biogen Idec Initiates Phase III Clinical Program of Oral Compound BG-12 for Multiple Sclerosis
HSMN NewsFeed - 9 Jan 2007
Labopharm Provides Update on Roll Out of Once-daily Tramadol Across Europe
Labopharm Provides Update on Roll Out of Once-daily Tramadol Across Europe
HSMN NewsFeed - 9 Jan 2007
Xytis Begins Phase II Clinical Study with Anatibant (XY2405) for Traumatic Brain Injury
Xytis Begins Phase II Clinical Study with Anatibant (XY2405) for Traumatic Brain Injury
HSMN NewsFeed - 8 Jan 2007
Xanthus Receives Orphan Drug Designation of Xanafide for the Treatment Of AML
Xanthus Receives Orphan Drug Designation of Xanafide for the Treatment Of AML
HSMN NewsFeed - 8 Jan 2007
Urigen N.A., Inc. Appoints Dennis Giesing, PhD As Director of Product Development
Urigen N.A., Inc. Appoints Dennis Giesing, PhD As Director of Product Development
HSMN NewsFeed - 8 Jan 2007
Cephalon Announces Positive Results from Two Phase 3 Clinical Trials of FENTORA(TM) in Breakthrough Pain
Cephalon Announces Positive Results from Two Phase 3 Clinical Trials of FENTORA(TM) in Breakthrough Pain
HSMN NewsFeed - 8 Jan 2007
Horizon Therapeutics Announces Special Protocol Assessment With FDA for Phase 3 Trial Program
Horizon Therapeutics Announces Special Protocol Assessment With FDA for Phase 3 Trial Program
HSMN NewsFeed - 8 Jan 2007
Progenics Pharmaceuticals Expands Senior Management Team and Board of Directors
Progenics Pharmaceuticals Expands Senior Management Team and Board of Directors
HSMN NewsFeed - 5 Jan 2007
Savient Pharmaceuticals Restructures Commercial Operations Following Launch of Authorized Generic
Savient Pharmaceuticals Restructures Commercial Operations Following Launch of Authorized Generic
HSMN NewsFeed - 5 Jan 2007
Hypnion Announces Positive and Robust Phase II Results for Novel Sleep Drug - HY10275
Hypnion Announces Positive and Robust Phase II Results for Novel Sleep Drug - HY10275
HSMN NewsFeed - 5 Jan 2007
Xytis Pharmaceuticals Names Dr. Vincent F. Simmon President, Chief Executive Officer and Director
Xytis Pharmaceuticals Names Dr. Vincent F. Simmon President, Chief Executive Officer and Director
HSMN NewsFeed - 4 Jan 2007
ChemoCentryx Appoints Juan Jaen, Ph.D., Senior Vice President, Drug Discovery
ChemoCentryx Appoints Juan Jaen, Ph.D., Senior Vice President, Drug Discovery
HSMN NewsFeed - 4 Jan 2007
Eli Lilly and Company Statement Regarding Today's New York Times Article - January 4, 2007
Eli Lilly and Company Statement Regarding Today's New York Times Article - January 4, 2007
HSMN NewsFeed - 4 Jan 2007
Victory Pharma, Inc. Announces Investigational New Drug MGX-006 Approved by the FDA
Victory Pharma, Inc. Announces Investigational New Drug MGX-006 Approved by the FDA
HSMN NewsFeed - 4 Jan 2007
Lilly and Plaintiffs' Attorneys Enter Into Agreements to Settle Zyprexa(R) Product Liability Litigation
Lilly and Plaintiffs' Attorneys Enter Into Agreements to Settle Zyprexa(R) Product Liability Litigation
HSMN NewsFeed - 4 Jan 2007
Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN(R) Clinical Practice Guidelines
Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN(R) Clinical Practice Guidelines
HSMN NewsFeed - 4 Jan 2007
Vical Initiates Pivotal Phase 3 Trial of Allovectin-7(R) as First-line Therapy for Metastatic Melanoma
Vical Initiates Pivotal Phase 3 Trial of Allovectin-7(R) as First-line Therapy for Metastatic Melanoma
HSMN NewsFeed - 4 Jan 2007
Court Affirms $7 Million in Damages for Innogenetics in Patent Infringement Suit
Court Affirms $7 Million in Damages for Innogenetics in Patent Infringement Suit
HSMN NewsFeed - 3 Jan 2007
Genaera Corporation Terminates EVIZON(TM) Clinical Program and Restructures
Genaera Corporation Terminates EVIZON(TM) Clinical Program and Restructures
HSMN NewsFeed - 3 Jan 2007
Conatus Pharmaceuticals Completes $27.5 Million Private Placement Financing
Conatus Pharmaceuticals Completes $27.5 Million Private Placement Financing
HSMN NewsFeed - 3 Jan 2007
Mallinckrodt Signs New Imaging and Radiopharmaceutical Agreements With Premier Purchasing Partners
Mallinckrodt Signs New Imaging and Radiopharmaceutical Agreements With Premier Purchasing Partners
HSMN NewsFeed - 3 Jan 2007
Mylan's Levothyroxine Sodium Tablets USP Approved as Generic Equivalent to Levothroid(R)
Mylan's Levothyroxine Sodium Tablets USP Approved as Generic Equivalent to Levothroid(R)
HSMN NewsFeed - 3 Jan 2007
Victory Pharma, Inc. Signs NAPRELAN(R) Agreement; US Field Sales Force to Expand
Victory Pharma, Inc. Signs NAPRELAN(R) Agreement; US Field Sales Force to Expand
HSMN NewsFeed - 3 Jan 2007
Sucampo Appoints Veteran Financial Executive Ronald W. Kaiser as Chief Financial Officer
Sucampo Appoints Veteran Financial Executive Ronald W. Kaiser as Chief Financial Officer
HSMN NewsFeed - 3 Jan 2007
Auriga Laboratories Appoints Richard K. Sampson as National Sales Director
Auriga Laboratories Appoints Richard K. Sampson as National Sales Director
HSMN NewsFeed - 3 Jan 2007
Hi-Tech Pharmacal Enters into Agreement with Victory Pharma, Inc. to Market and Distribute Naprelan(R)
Hi-Tech Pharmacal Enters into Agreement with Victory Pharma, Inc. to Market and Distribute Naprelan(R)
HSMN NewsFeed - 3 Jan 2007
D-Pharm Announces Positive Phase IIb Trial Results for DP-b99 in Acute Stroke Patients
D-Pharm Announces Positive Phase IIb Trial Results for DP-b99 in Acute Stroke Patients
HSMN NewsFeed - 3 Jan 2007
Exelixis Signs Co-Development Agreement With Genentech for Small Molecule Oncology Compound
Exelixis Signs Co-Development Agreement With Genentech for Small Molecule Oncology Compound
HSMN NewsFeed - 2 Jan 2007
Hospitals, Healthcare Providers to Save with Premier Plasma Distribution Agreement with FFF Enterprises
Hospitals, Healthcare Providers to Save with Premier Plasma Distribution Agreement with FFF Enterprises
HSMN NewsFeed - 2 Jan 2007
Radius Appoints Nick Harvey Senior Vice President and Chief Financial Officer
Radius Appoints Nick Harvey Senior Vice President and Chief Financial Officer
HSMN NewsFeed - 2 Jan 2007
Ranbaxy Granted Final U.S. FDA Approval to Manufacture and Market Atenolol Tablets
Ranbaxy Granted Final U.S. FDA Approval to Manufacture and Market Atenolol Tablets
HSMN NewsFeed - 29 Dec 2006
Bradley Pharmaceuticals Announces Launch of Authorized Generic of Pamine(R) (methscopolamine bromide)
Bradley Pharmaceuticals Announces Launch of Authorized Generic of Pamine(R) (methscopolamine bromide)
HSMN NewsFeed - 29 Dec 2006
Merck & Co., Inc. Announces Completion of Acquisition of Sirna Therapeutics, Inc.
Merck & Co., Inc. Announces Completion of Acquisition of Sirna Therapeutics, Inc.
HSMN NewsFeed - 29 Dec 2006
Savient Pharmaceuticals Announces Launch of Authorized Generic of Oxandrin(R) with Watson Pharmaceuticals
Savient Pharmaceuticals Announces Launch of Authorized Generic of Oxandrin(R) with Watson Pharmaceuticals
HSMN NewsFeed - 29 Dec 2006
Oscient Pharmaceuticals Amends FACTIVE License Agreement with LG Life Sciences
Oscient Pharmaceuticals Amends FACTIVE License Agreement with LG Life Sciences
HSMN NewsFeed - 28 Dec 2006
Stiefel Laboratories, Inc. Completes Acquisition of Connetics Corporation
Stiefel Laboratories, Inc. Completes Acquisition of Connetics Corporation
HSMN NewsFeed - 28 Dec 2006
Boca Pharmacal Receives FDA Approval for Generic Pamine(R) and Pamine(R) Forte Tablets
Boca Pharmacal Receives FDA Approval for Generic Pamine(R) and Pamine(R) Forte Tablets
HSMN NewsFeed - 28 Dec 2006
Landmark Tykerb(R) (Lapatinib) Data Published in the New England Journal of Medicine
Landmark Tykerb(R) (Lapatinib) Data Published in the New England Journal of Medicine
HSMN NewsFeed - 28 Dec 2006
SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple Therapy Hepatitis C Clinical Trial
SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple Therapy Hepatitis C Clinical Trial
HSMN NewsFeed - 27 Dec 2006
Protiva Dismisses, Without Prejudice, Its California Litigation Against Inex
Protiva Dismisses, Without Prejudice, Its California Litigation Against Inex
HSMN NewsFeed - 27 Dec 2006
ADVENTRX Initiates CoFactor Phase II Clinical Trial in Refractory Breast Cancer
ADVENTRX Initiates CoFactor Phase II Clinical Trial in Refractory Breast Cancer
HSMN NewsFeed - 27 Dec 2006
Dr. Reddy's Announces Final Approval of Ondansetron Tablets with 180-Days of Marketing Exclusivity
Dr. Reddy's Announces Final Approval of Ondansetron Tablets with 180-Days of Marketing Exclusivity
HSMN NewsFeed - 26 Dec 2006
Astellas Pharma US, Inc. Submits Supplemental New Drug Application For Antifungal Product MYCAMINE(R)
Astellas Pharma US, Inc. Submits Supplemental New Drug Application For Antifungal Product MYCAMINE(R)
HSMN NewsFeed - 26 Dec 2006
Cardinal Health Announces Resolution of New York Attorney General Investigation
Cardinal Health Announces Resolution of New York Attorney General Investigation
HSMN NewsFeed - 26 Dec 2006
pSivida Enters Licensing Negotiations with Major Global Pharma for Drug Delivery Technologies
pSivida Enters Licensing Negotiations with Major Global Pharma for Drug Delivery Technologies
HSMN NewsFeed - 26 Dec 2006
Par Pharmaceutical Receives Approval for Ondansetron Orally Disintegrating Tablets
Par Pharmaceutical Receives Approval for Ondansetron Orally Disintegrating Tablets
HSMN NewsFeed - 26 Dec 2006
Telik Reports Preliminary Results on ASSIST-1, ASSIST-2 and ASSIST-3 Phase 3 Clinical Trials
Telik Reports Preliminary Results on ASSIST-1, ASSIST-2 and ASSIST-3 Phase 3 Clinical Trials
HSMN NewsFeed - 26 Dec 2006
IDM Pharma Announces Acceptance for Review of the NDA for Junovan(TM) (Mifamurtide)
IDM Pharma Announces Acceptance for Review of the NDA for Junovan(TM) (Mifamurtide)
HSMN NewsFeed - 26 Dec 2006
Faropenem Phase III Clinical Trial Stopped to Consider Exclusion of Ketek Comparator
Faropenem Phase III Clinical Trial Stopped to Consider Exclusion of Ketek Comparator
HSMN NewsFeed - 22 Dec 2006
FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
HSMN NewsFeed - 22 Dec 2006
Valeant Pharmaceuticals Sells Discovery and Preclinical Assets to Ardea Biosciences
Valeant Pharmaceuticals Sells Discovery and Preclinical Assets to Ardea Biosciences
HSMN NewsFeed - 22 Dec 2006
Pharmacyclics Submits New Drug Application for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Pharmacyclics Submits New Drug Application for Xcytrin for the Treatment of Lung Cancer Brain Metastases
HSMN NewsFeed - 22 Dec 2006
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
HSMN NewsFeed - 22 Dec 2006
SciClone and Sigma-Tau Announce Positive Interim Survival Data From Large Phase 2 Malignant Melanoma Trial
SciClone and Sigma-Tau Announce Positive Interim Survival Data From Large Phase 2 Malignant Melanoma Trial
HSMN NewsFeed - 22 Dec 2006
Synthetic Blood Reports Positive Preliminary Results From Traumatic Brain Injury Clinical Trial
Synthetic Blood Reports Positive Preliminary Results From Traumatic Brain Injury Clinical Trial
HSMN NewsFeed - 21 Dec 2006
Depomed Receives $10 Million License Fee from Esprit and Withdraws Arbitration Proceeding
Depomed Receives $10 Million License Fee from Esprit and Withdraws Arbitration Proceeding
HSMN NewsFeed - 21 Dec 2006
Eli Lilly and Company Statement Regarding Today's New York Times Article - December 21, 2006
Eli Lilly and Company Statement Regarding Today's New York Times Article - December 21, 2006
HSMN NewsFeed - 21 Dec 2006
Accentia Biopharmaceuticals in Discussions with Pharmaceutical Companies on SinuNase Partnership
Accentia Biopharmaceuticals in Discussions with Pharmaceutical Companies on SinuNase Partnership
HSMN NewsFeed - 21 Dec 2006
Alfacell Corporation Files for U.S. Orphan Drug Designation for ONCONASE(R)
Alfacell Corporation Files for U.S. Orphan Drug Designation for ONCONASE(R)
HSMN NewsFeed - 21 Dec 2006
Genzyme Files for Approval of Sevelamer Carbonate for Patients on Dialysis
Genzyme Files for Approval of Sevelamer Carbonate for Patients on Dialysis
HSMN NewsFeed - 21 Dec 2006
Ranbaxy Granted Final FDA Approval to Market Simvastatin 5, 10, 20 and 40 mg Tablets
Ranbaxy Granted Final FDA Approval to Market Simvastatin 5, 10, 20 and 40 mg Tablets
HSMN NewsFeed - 21 Dec 2006
Anika Therapeutics Receives FDA Approval for Its Cosmetic Tissue Augmentation Product
Anika Therapeutics Receives FDA Approval for Its Cosmetic Tissue Augmentation Product
HSMN NewsFeed - 21 Dec 2006
Critical Therapeutics' Board of Directors Appoints Frank Thomas as Chief Executive Officer
Critical Therapeutics' Board of Directors Appoints Frank Thomas as Chief Executive Officer
HSMN NewsFeed - 21 Dec 2006
Isis Development Partner iCo Therapeutics Files IND for Antisense Drug to Treat Eye Disease
Isis Development Partner iCo Therapeutics Files IND for Antisense Drug to Treat Eye Disease
HSMN NewsFeed - 21 Dec 2006
Data Monitoring Committee Recommends Closing Enrollment in Recurrent Glioblastoma Study
Data Monitoring Committee Recommends Closing Enrollment in Recurrent Glioblastoma Study
HSMN NewsFeed - 20 Dec 2006
Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth
Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth
HSMN NewsFeed - 20 Dec 2006
Australian Federal Court Grants Favorable Decision to Ranbaxy on Pfizer's Atorvastatin Patent
Australian Federal Court Grants Favorable Decision to Ranbaxy on Pfizer's Atorvastatin Patent
HSMN NewsFeed - 20 Dec 2006
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
HSMN NewsFeed - 20 Dec 2006
Sciele Pharma Signs Exclusive Zovirax(R) Promotional Agreement with Biovail
Sciele Pharma Signs Exclusive Zovirax(R) Promotional Agreement with Biovail
HSMN NewsFeed - 20 Dec 2006
Sanofi pasteur Influenza Vaccine Production Tops 170 Million Doses in 2006
Sanofi pasteur Influenza Vaccine Production Tops 170 Million Doses in 2006
HSMN NewsFeed - 20 Dec 2006
Dynavax Initiates Pivotal Phase 3 Trial for HEPLISAV(TM), Hepatitis B Vaccine
Dynavax Initiates Pivotal Phase 3 Trial for HEPLISAV(TM), Hepatitis B Vaccine
HSMN NewsFeed - 20 Dec 2006
Labopharm submits response to approvable letter for once-daily Tramadol to FDA
Labopharm submits response to approvable letter for once-daily Tramadol to FDA
HSMN NewsFeed - 20 Dec 2006
Biopure Announces Next Steps for Navy's Proposed 'Resus' Trauma Trial of Hemopure(R)
Biopure Announces Next Steps for Navy's Proposed 'Resus' Trauma Trial of Hemopure(R)
HSMN NewsFeed - 19 Dec 2006
Reliant Pharmaceuticals Files Patent Infringement Lawsuit Against Par Pharmaceutical
Reliant Pharmaceuticals Files Patent Infringement Lawsuit Against Par Pharmaceutical
HSMN NewsFeed - 19 Dec 2006
Northfield Laboratories Reports Preliminary Top-Line Data in Pivotal Phase III Trauma Study
Northfield Laboratories Reports Preliminary Top-Line Data in Pivotal Phase III Trauma Study
HSMN NewsFeed - 19 Dec 2006
Neurorecovery, Inc. Updates Clinical Development Program for Guillain-Barré Syndrome (GBS)
Neurorecovery, Inc. Updates Clinical Development Program for Guillain-Barré Syndrome (GBS)
HSMN NewsFeed - 19 Dec 2006
Adrian Rawcliffe to Lead GlaxoSmithKline's Worldwide Business Development
Adrian Rawcliffe to Lead GlaxoSmithKline's Worldwide Business Development
HSMN NewsFeed - 19 Dec 2006
PsychoGenics Announces Drug Discovery and Development Agreement With Eli Lilly and Company
PsychoGenics Announces Drug Discovery and Development Agreement With Eli Lilly and Company
HSMN NewsFeed - 19 Dec 2006
Trillium's TTI-1612 product receives orphan drug designation in Europe and the United States
Trillium's TTI-1612 product receives orphan drug designation in Europe and the United States
HSMN NewsFeed - 19 Dec 2006
Bradley Pharmaceuticals Announces FDA Approval of Elestrin(TM) (estradiol gel 0.06%)
Bradley Pharmaceuticals Announces FDA Approval of Elestrin(TM) (estradiol gel 0.06%)
HSMN NewsFeed - 19 Dec 2006
Endo Pharmaceuticals Submits Citizen Petition to FDA Regarding Lidoderm(R)
Endo Pharmaceuticals Submits Citizen Petition to FDA Regarding Lidoderm(R)
HSMN NewsFeed - 18 Dec 2006
Pfizer Board of Directors Names Chief Executive Officer Jeffrey B. Kindler Chairman of the Board
Pfizer Board of Directors Names Chief Executive Officer Jeffrey B. Kindler Chairman of the Board
HSMN NewsFeed - 18 Dec 2006
BioMarin Announces Positive Results From Phase 3 Extension Study of Phenoptin for PKU
BioMarin Announces Positive Results From Phase 3 Extension Study of Phenoptin for PKU
HSMN NewsFeed - 18 Dec 2006
Statement from Eli Lilly and Company: Response to The New York Times Article from December 18, 2006
Statement from Eli Lilly and Company: Response to The New York Times Article from December 18, 2006
HSMN NewsFeed - 18 Dec 2006
OSI Pharmaceuticals Announces Appointment of Pablo J. Cagnoni, M.D. as Chief Medical Officer
OSI Pharmaceuticals Announces Appointment of Pablo J. Cagnoni, M.D. as Chief Medical Officer
HSMN NewsFeed - 18 Dec 2006
Pipex Pharmaceuticals, Inc. Completes Corporate Name Change and New Ticker Symbol
Pipex Pharmaceuticals, Inc. Completes Corporate Name Change and New Ticker Symbol
HSMN NewsFeed - 18 Dec 2006
Anthracyclines May Not Be for Everyone: Report From the 29th Annual San Antonio Breast Cancer Symposium
Anthracyclines May Not Be for Everyone: Report From the 29th Annual San Antonio Breast Cancer Symposium
HSMN NewsFeed - 18 Dec 2006
Depomed Delivers Notice of Breach and Demand for Arbitration to Esprit Pharma
Depomed Delivers Notice of Breach and Demand for Arbitration to Esprit Pharma
HSMN NewsFeed - 18 Dec 2006
ZLB Behring Completes Purchase of CytoGam(R) Immunoglobulin Therapy From MedImmune
ZLB Behring Completes Purchase of CytoGam(R) Immunoglobulin Therapy From MedImmune
HSMN NewsFeed - 18 Dec 2006
Aerovance Adds Accomplished Product Commercialization Executive to Leadership Team
Aerovance Adds Accomplished Product Commercialization Executive to Leadership Team
HSMN NewsFeed - 18 Dec 2006
American Cancer Society Journal Article Reports New Data Regarding Repeated Administration of QUADRAMET(R)
American Cancer Society Journal Article Reports New Data Regarding Repeated Administration of QUADRAMET(R)
HSMN NewsFeed - 18 Dec 2006
Repros Reports Proellex Achieves Statistically Significant Pain Reduction in Endometriosis Trial
Repros Reports Proellex Achieves Statistically Significant Pain Reduction in Endometriosis Trial
HSMN NewsFeed - 18 Dec 2006
Successful Study With Tracleer(r) in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension
Successful Study With Tracleer(r) in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension
HSMN NewsFeed - 15 Dec 2006
Caraco Pharmaceutical Laboratories Ltd. to Market Extended Phenytoin Sodium Capsules, USP 100mg
Caraco Pharmaceutical Laboratories Ltd. to Market Extended Phenytoin Sodium Capsules, USP 100mg
HSMN NewsFeed - 15 Dec 2006
Lipoxen Announces $75M Agreement With Baxter to Develop New Blood Clotting Factors
Lipoxen Announces $75M Agreement With Baxter to Develop New Blood Clotting Factors
HSMN NewsFeed - 14 Dec 2006
EPIX Pharmaceuticals to File Appeal with the Center for Drug Evaluation and Research for Vasovist(TM)
EPIX Pharmaceuticals to File Appeal with the Center for Drug Evaluation and Research for Vasovist(TM)
HSMN NewsFeed - 14 Dec 2006
New Data On Pfizer's Aromasin and Ellence to Be Presented at San Antonio Breast Cancer Symposium
New Data On Pfizer's Aromasin and Ellence to Be Presented at San Antonio Breast Cancer Symposium
HSMN NewsFeed - 14 Dec 2006
Robert Brown Joins Biothera as Senior Vice President, Corporate Development
Robert Brown Joins Biothera as Senior Vice President, Corporate Development
HSMN NewsFeed - 14 Dec 2006
Court Denies Novo Nordisk's Motion for Preliminary Injunction Against Exubera
Court Denies Novo Nordisk's Motion for Preliminary Injunction Against Exubera
HSMN NewsFeed - 14 Dec 2006
Ranbaxy Is Granted Final Approval to Manufacture and Market Cefprozil Anti- Infective Tablets
Ranbaxy Is Granted Final Approval to Manufacture and Market Cefprozil Anti- Infective Tablets
HSMN NewsFeed - 14 Dec 2006
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
HSMN NewsFeed - 14 Dec 2006
Adolor Announces Discontinuation of Sales Force and Other Selected Work Force Reductions
Adolor Announces Discontinuation of Sales Force and Other Selected Work Force Reductions
HSMN NewsFeed - 14 Dec 2006
Jenken Biosciences Receives FDA Clearance for Phase II Trial of Lead Compound
Jenken Biosciences Receives FDA Clearance for Phase II Trial of Lead Compound
HSMN NewsFeed - 14 Dec 2006
LigoCyte Pharmaceuticals Announces the Addition of Dr. Donald deBethizy to Their Board of Directors
LigoCyte Pharmaceuticals Announces the Addition of Dr. Donald deBethizy to Their Board of Directors
HSMN NewsFeed - 13 Dec 2006
Access Pharmaceuticals Receives MuGard(TM) Marketing Clearance From the FDA
Access Pharmaceuticals Receives MuGard(TM) Marketing Clearance From the FDA
HSMN NewsFeed - 13 Dec 2006
Exercise and Physical Rehabilitation Specialist Joins Endovasc's Board of Directors
Exercise and Physical Rehabilitation Specialist Joins Endovasc's Board of Directors
HSMN NewsFeed - 13 Dec 2006
Cyclacel Submits IND of CYC116 an Aurora Kinase and VEGRF2 Inhibitor to Treat Cancer
Cyclacel Submits IND of CYC116 an Aurora Kinase and VEGRF2 Inhibitor to Treat Cancer
HSMN NewsFeed - 13 Dec 2006
FDA Accepts New Drug Application for SANCTURA XR(TM) Submitted by Indevus
FDA Accepts New Drug Application for SANCTURA XR(TM) Submitted by Indevus
HSMN NewsFeed - 13 Dec 2006
Ambit Biosciences Announces Establishment of Clinical Oncology Advisory Board
Ambit Biosciences Announces Establishment of Clinical Oncology Advisory Board
HSMN NewsFeed - 12 Dec 2006
EpiCept Announces Relocation of Corporate Headquarters to Tarrytown, New York
EpiCept Announces Relocation of Corporate Headquarters to Tarrytown, New York
HSMN NewsFeed - 12 Dec 2006
United Therapeutics Affiliate Initiates First-Ever Gene-Therapy Trial for Pulmonary Arterial Hypertension
United Therapeutics Affiliate Initiates First-Ever Gene-Therapy Trial for Pulmonary Arterial Hypertension
HSMN NewsFeed - 12 Dec 2006
Ilypsa Announces Promotion of Gerrit Klaerner, Ph.D. to Senior Vice President and Chief Business Officer
Ilypsa Announces Promotion of Gerrit Klaerner, Ph.D. to Senior Vice President and Chief Business Officer
HSMN NewsFeed - 12 Dec 2006
Abbott and Enanta Form Worldwide Alliance to Develop and Commercialize HCV Protease Inhibitors
Abbott and Enanta Form Worldwide Alliance to Develop and Commercialize HCV Protease Inhibitors
HSMN NewsFeed - 12 Dec 2006
EntreMed Presents Data on the Combination of Panzem(R) and Velcade(R) in Multiple Myeloma
EntreMed Presents Data on the Combination of Panzem(R) and Velcade(R) in Multiple Myeloma
HSMN NewsFeed - 12 Dec 2006
Northern Therapeutics and MaxCyte Initiate Landmark Engineered Cell Therapy Trial for Fatal Lung Disease
Northern Therapeutics and MaxCyte Initiate Landmark Engineered Cell Therapy Trial for Fatal Lung Disease
HSMN NewsFeed - 12 Dec 2006
Donald S. Masters, Ph.D. Named New President and CEO of Triton BioSystems, Inc.
Donald S. Masters, Ph.D. Named New President and CEO of Triton BioSystems, Inc.
HSMN NewsFeed - 12 Dec 2006
Medicure Announces Special Protocol Assessment With the FDA For Phase III MEND-CABG II Study
Medicure Announces Special Protocol Assessment With the FDA For Phase III MEND-CABG II Study
HSMN NewsFeed - 12 Dec 2006
Auxilium Pharmaceuticals, Inc. Announces Distribution Agreement With Paladin Labs for Testim(R) in Canada
Auxilium Pharmaceuticals, Inc. Announces Distribution Agreement With Paladin Labs for Testim(R) in Canada
HSMN NewsFeed - 12 Dec 2006
Cell Therapeutics, Inc. (CTI) Announces Pixantrone Combination Regimen Produces High Response Rates
Cell Therapeutics, Inc. (CTI) Announces Pixantrone Combination Regimen Produces High Response Rates
HSMN NewsFeed - 11 Dec 2006
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
HSMN NewsFeed - 11 Dec 2006
Introgen Announces New Clinical Data Confirming ADVEXIN(R) Survival Benefit
Introgen Announces New Clinical Data Confirming ADVEXIN(R) Survival Benefit
HSMN NewsFeed - 11 Dec 2006
Multiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) for Injection
Multiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) for Injection
